De Soto planners have delayed approval of Merck Animal Health's site plan to review fire lane and traffic flow details for the animal vaccine maker's expansion.

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year. Merck is paying $221.50 cash per share of Cidara, a San ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Merck said Friday it would buy Cidara Therapeutics, the maker of an ...

Germany and Taiwan marked a symbolic convergence of politics, culture and industrial strategy on Tuesday evening as the ...

Merck MRK-1.35%decrease; red down pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics CDTX-0.22%decrease; red down pointing triangle in a move that ...

The Trump administration has changed guidance for a federal broadband grant program, urging states to prioritize lower-cost internet projects. Kansas received $451 million for broadband expansion but ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to counter sales cliffs for two of its biggest drugs. Merck has been vocal ...

Nov 13 (Reuters) - Merck (MRK.N), opens new tab is closing in on a deal to buy Cidara Therapeutics (CDTX.O), opens new tab in a deal valuing the biotechnology company at a premium to its $3.3 billion ...